Pfizer's Pipeline Looks Primed to Deliver

The stock of the world's largest drugmaker has been a laggard lately. But that could be soon changing if analysts who are pointing to a solid lineup of new products are right. They think the giant can easily offset the patent loss for Lipitor.

Biz Brief: Stroke Drug Study Ends Early on Positive Result

Pfizer and Bristol-Myers Squibb said on Thursday that they've decided to halt a clinical trial several months early because data so far suggested the experimental drug apixaban was more effective than aspirin in preventing strokes among patients.